AYTU BIOPHARMA, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on December 13, 2022, regarding events occurring on December 12, 2022. The Company is a Delaware corporation with its principal executive offices in Englewood, Colorado, and its common stock trades on The NASDAQ Stock Market LLC under the symbol "AYTU".
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on corporate governance and accounting firm changes.
Material Changes
- Dismissal of Accountant: The Audit Committee dismissed Plante & Moran PLLC as the Company's independent registered public accounting firm.
- Engagement of New Accountant: Grant Thornton LLP was appointed as the new independent registered public accounting firm for the fiscal year ending June 30, 2023.
- Going Concern Warning: Plante & Moran's report for the fiscal year ended June 30, 2022, included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
- Material Weakness Identified: The Company disclosed a material weakness in internal control over financial reporting related to the analysis of impairment for long-lived assets, including goodwill and intangible assets. This stemmed from the improper aggregation of assets during the June 30, 2021 assessment, which incorrectly concluded no impairment had occurred.
Outlook, Risks, and Management Commentary
Management stated that the material weakness did not result in a revision of previously issued financial statements but could have led to a material misstatement if unaddressed. Remediation efforts included incorporating third-party providers to review assumptions and computations for impairment analysis. The Company believes its controls are now designed properly and operating effectively. No disagreements or reportable events occurred between the Company and Plante & Moran, other than the previously reported material weakness. No consultations regarding accounting principles or audit opinions were held with Grant Thornton prior to their engagement.
Investor Verification Checklist
- Verify the Company's current liquidity position and ability to continue as a going concern, given the prior auditor's warning.
- Review the Company's remediation plan for the material weakness regarding long-lived asset impairment testing.
- Confirm the transition timeline and scope of work for the new auditor, Grant Thornton LLP.
- Examine future filings for any restatements of financial statements related to the identified impairment assessment errors.